Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated. Methods In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral roflumilast 500 mu g or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). The primary endpoint was change in prebronchodilator forced expiratory volume in 1s (FEV(1)). Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, number NCT00313209 for M2-127, and NCT00424268 for M2-128. Findings In the salmeterol plus roflumilast trial, 466 patients were assigned to and treated with roflumilast and 467 with placebo; in the tiotropium plus roflumilast trial, 371 patients were assigned to and treated with roflumilast and 372 with placebo. Compared with placebo, roflumilast consistently improved mean prebronchodilator FEV(1) by 49 mL (p<0.0001) in patients treated with salmeterol, and 80 mL (p<0.0001) in those treated with tiotropium. Similar improvement in postbronchodilator FEV(1) was noted in both groups. Furthermore, roflumilast had beneficial effects on other lung function measurements and on selected patient-reported outcomes in both groups. Nausea, diarrhoea, weight loss, and, to a lesser extent, headache were more frequent in patients in the roflumilast groups. These adverse events were associated with increased patient withdrawal. Interpretation Roflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients.

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials / Leonardo M., Fabbri; Peter M. A., Calverley; Jose Luis Izquierdo, Alonso; Daniela S., Bundschuh; Manja, Brose; Fernando J., Martinez; Kf M., Rabe; M., Study Groups Abdulla; I., Abdullah; M., Adler; Aguilaniu, ; I., Albert; C., Almonacid; A., Altés; S., Amaducci; J., Angrill; J. M., Antonana; H., Artner; B., Balint; T. A., Bantje; F., Barbe; E., Bateman; E., Bauchnect; J., Belda; L., Bernabeu; A., Bettendorf; M., Blagden; R., Blanquer; L., Blecher; F., Bonnaud; J., Bourbeau; G. R., Boyer; C., Brotons; A. H., Bruning; C., Bucca; G. E., Burns; B. B., Von Der Heydt; Caldwell, ; G. W., Canonica; J., Carter; V., Chan; K. R., Chapman; G., Chapman; D., Cheung; E., Chiner; A., Chopra; E., Clini; P., Coulet; B., Craig; L., Croonenborghs; M., Czompó; R. W., Dal Negro; T., Dapper; C. S., De Graaff; L., Ramos Pde; D. R., De Munck; M., Decramer; A., Delobbe; W., Denier; L., De Teresa; A., Dhar; G., Di Maria; J., Dupouy; G., Duschek; J., Echave; C., Esteban; I. S., Farmer; A., Flemale; P., Fletcher; Foden, ; L., Fouquert; K. H., Franz; Frognier, ; M., Gagnon; Mdel M., Garcia; G., Garelli; U., Gehling; T., Ginko; B., Glekin; T., Gooding; A., Graham; P., Greillier; J. V., Greses; J., Grillenberger; B., Gross; H., Grygier; Z., Gyori; Harper, ; S., Henein; J. L., Heredia; P., Hernandez; M., Hoefer; V., Hoffstein; K., Holgate; W., Holler; G., Holub; L., Homik; P. A., Houle; C., Hutter; P., Hyvernat; E. M., Irusen; A., Jackson; W., Janisty; J. Y., Jasnot; J., Joubert; G., Juhasz; H., Jullian; H., Kafe; P., Kelly; J., Kidney; K., Killian; H., Kinch; D. L., Kirsten; U., Kleinecke Pohl; K., Korlipara; L. P., Krige; A., Kroker; A. F., Kuipers; M., Labrecque; P., Larivee; C., Laskowitz; C., Le Merre; F., Lemoigne; A., Ludwig Sengpiel; M., Luengo; R., Luton; W., Macnee; S. M., Ali; F., Maltais; A., Mansur; D., Marciniuk; A., Marin; P., Martin; J. B., Martinot; F., Mazza; M. C., Bride; B., Mcdonald; C., Mckinnon; A., Mclvor; D., Mcnally; P. M., Mengeot; J., Messner; G., Moder; P., Mooney; A. M., Moretti; D., Muller; C., Murio; S., Nardini; A., Nel; Ochoa, ; D. E., Saracho Jo; P., Paggiaro; B., Paradis; J., Patrick; R., Peche; C., Pellicer; T., Perez; E., Perez; L. A., De Llano; G., Philteos; W. R., Pieters; B., Pigearias; W., Pohl; R., Popovic; M., Prins; H., Querfurt; K., Rajkay; G., Ras; J., Road; J., Roig; A. C., Roldaan; M., Rolke; D., Rozen; F., Sanchez Toril; N., Savani; L., Savary; M., Schiavina; H., Schiesbühl; A. J., Schreurs; W., Schröder Babo; W., Schurmann; V., Seiz; C., Sevette; R., Sharma; C., Shum; H. E., Damsté; A., Smithers; J. J., Soler; H., Steffen; U., Steinhauser; M., Sweilem; G., Tellier; B., Terol; Terzano, Claudio; M., Timar; G., Toma; P. T., Monserrat; H. A., Trauth; E., Valyon; Brande Van, Den; J. A., Van Noord; J. V., Vaquer; H. V., Hernandez Hector; G., Vereecken; C., Verkindre; M., Vigh; J. J., Viljoen; W., Vincken; I., Vinkler; S., Visser; L., Volgmann; W., Vorderstrasse; R., Voves; F., Vrancken; H. H., Weber; P. L., Wielders; P., Willoughby; J., Wurtz; W., Yang; M., Zabaleta; W., Zachgo; A., Zanini; M., Zeiner; M., Zeiner; H., Michael; J., Grillenberger; G., Holub; R., Popovic; J., Wurtz; G., Duschek; W., Janistyn; C., Hutter; H., Schiesbühl; J., Messner; W., Pohl; M., Sweilem; R., Voves; W., Holler; G., Moder; W., Vincken; M., Decramer; J. B., Martinot; L., Croonenborghs; D., Rozen; G., Vereecken; W., Denier; A., Flemale; F., Vrancken; A., Delobbe; Frognier, ; R., Peche; Brande Van, Den; A., Delobbe; P. M., Mengeot; F., Maltais; J., Bourbeau; A., Mclvor; P., Larivee; B., Craig; J., Road; P. A., Houle; W., Yang; K. R., Chapman; M., Gagnon; R., Luton; P., Hernandez; L., Homik; D., Marciniuk; S., Henein; V., Hoffstein; K., Killian; B., Paradis; J., Carter; M., Labrecque; P., Willoughby; R., Abdulla; G., Philteos; V., Chan; A., Dhar; G., Tellier; P., Hyvernat; T., Perez; H., Kafe; J., Dupouy; P., Coulet; B., Pigearias; H., Jullian; L., Fouquert; G. R., Boyer; L., Bernabeu; C., Verkindre; A., Bettendorf; J. Y., Jasnot; Aguilaniu, ; L., Savary; F., Bonnaud; F., Lemoigne; C., Sevette; P., Greillier; D., Muller; B., Terol; C., Le Merre; M., Hoefer; H. A., Trauth; H., Querfurt; L., Volgmann; U., Steinhauser; T., Ginko; K. H., Franz; A., Kroker; W., Schröder Babo; U., Gehling; P., Martin; A., Ludwig Sengpiel; T., Dapper; W., Zachgo; U., Kleinecke Pohl; M., Rolke; L., Blecher; H., Steffen; H., Grygier; H. H., Weber; W., Vorderstrasse; W., Schurmann; C., Laskowitz; V., Seiz; B., Gross; B. B., Von Der Heydt; E., Valyon; M., Czompó; G., Juhasz; Z., Gyori; M., Timar; I., Albert; K., Rajkay; E., Bauchnect; I., Vinkler; B., Balint; M., Vigh; S., Amaducci; G. W., Canonica; G., Di Maria; A., Zanini; P., Paggiaro; M., Schiavina; R. W., Dal Negro; F., Mazza; G., Toma; C., Bucca; C., Terzano; G., Garelli; A. M., Moretti; S., Nardini; L., Fabbri; M. P., Barbaro; G. W., Canonica; E., Clini; P. L., Wielders; A. F., Kuipers; C. S., De Graaff; D., Cheung; H. E., Damsté; W. R., Pieters; A. J., Schreurs; J. A., Van Noord; D. R., De Munck; T. A., Bantje; A. C., Roldaan; E. M., Irusen; G., Ras; M., Prins; E., Bateman; J., Joubert; I., Abdullah; S., Visser; A. H., Bruning; J. J., Viljoen; L. P., Krige; A., Nel; D. L., Kirsten; J. L., Izquierdo; Mdel M., Garcia; C., Shum; E., Chiner; J. L., Heredia; M., Zabaleta; M., Luengo; D. E., Saracho Jo; P. T., Monserrat; J. V., Vaquer; A., Marin; J., Angrill; C., Brotons; A., Altés; E., Perez; F., Sanchez Toril; Pde L., Ramos; H. V., Hernandez Hector; C., Almonacid; J., Belda; J. M., Antonana; R., Blanquer; J. J., Soler; F., Barbe; C., Murio; L., De Teresa; C., Esteban; J. V., Greses; C., Pellicer; J., Echave; L. A., De Llano; J., Roig; A., Chopra; N., Savani; B., Glekin; A., Jackson; M., Blagden; R., Sharma; G., Chapman; D., Mcnally; J., Patrick; M. C., Bride; G. E., Burns; J., Kidney; P., Kelly; W., Macnee; H., Kinch; S. M., Ali; M., Adler; M., Blagden; P., Mooney; Caldwell, ; I. S., Farmer; A., Graham; K., Holgate; P., Fletcher; K., Korlipara; B., Mcdonald; C., Mckinnon; A., Smithers; A., Mansur; T., Gooding; Harper, Ochoa; Foden,. - In: THE LANCET. - ISSN 0140-6736. - 374:9691(2009), pp. 695-703. [10.1016/s0140-6736(09)61252-6]

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

TERZANO, Claudio;
2009

Abstract

Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated. Methods In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral roflumilast 500 mu g or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). The primary endpoint was change in prebronchodilator forced expiratory volume in 1s (FEV(1)). Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, number NCT00313209 for M2-127, and NCT00424268 for M2-128. Findings In the salmeterol plus roflumilast trial, 466 patients were assigned to and treated with roflumilast and 467 with placebo; in the tiotropium plus roflumilast trial, 371 patients were assigned to and treated with roflumilast and 372 with placebo. Compared with placebo, roflumilast consistently improved mean prebronchodilator FEV(1) by 49 mL (p<0.0001) in patients treated with salmeterol, and 80 mL (p<0.0001) in those treated with tiotropium. Similar improvement in postbronchodilator FEV(1) was noted in both groups. Furthermore, roflumilast had beneficial effects on other lung function measurements and on selected patient-reported outcomes in both groups. Nausea, diarrhoea, weight loss, and, to a lesser extent, headache were more frequent in patients in the roflumilast groups. These adverse events were associated with increased patient withdrawal. Interpretation Roflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients.
2009
01 Pubblicazione su rivista::01a Articolo in rivista
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials / Leonardo M., Fabbri; Peter M. A., Calverley; Jose Luis Izquierdo, Alonso; Daniela S., Bundschuh; Manja, Brose; Fernando J., Martinez; Kf M., Rabe; M., Study Groups Abdulla; I., Abdullah; M., Adler; Aguilaniu, ; I., Albert; C., Almonacid; A., Altés; S., Amaducci; J., Angrill; J. M., Antonana; H., Artner; B., Balint; T. A., Bantje; F., Barbe; E., Bateman; E., Bauchnect; J., Belda; L., Bernabeu; A., Bettendorf; M., Blagden; R., Blanquer; L., Blecher; F., Bonnaud; J., Bourbeau; G. R., Boyer; C., Brotons; A. H., Bruning; C., Bucca; G. E., Burns; B. B., Von Der Heydt; Caldwell, ; G. W., Canonica; J., Carter; V., Chan; K. R., Chapman; G., Chapman; D., Cheung; E., Chiner; A., Chopra; E., Clini; P., Coulet; B., Craig; L., Croonenborghs; M., Czompó; R. W., Dal Negro; T., Dapper; C. S., De Graaff; L., Ramos Pde; D. R., De Munck; M., Decramer; A., Delobbe; W., Denier; L., De Teresa; A., Dhar; G., Di Maria; J., Dupouy; G., Duschek; J., Echave; C., Esteban; I. S., Farmer; A., Flemale; P., Fletcher; Foden, ; L., Fouquert; K. H., Franz; Frognier, ; M., Gagnon; Mdel M., Garcia; G., Garelli; U., Gehling; T., Ginko; B., Glekin; T., Gooding; A., Graham; P., Greillier; J. V., Greses; J., Grillenberger; B., Gross; H., Grygier; Z., Gyori; Harper, ; S., Henein; J. L., Heredia; P., Hernandez; M., Hoefer; V., Hoffstein; K., Holgate; W., Holler; G., Holub; L., Homik; P. A., Houle; C., Hutter; P., Hyvernat; E. M., Irusen; A., Jackson; W., Janisty; J. Y., Jasnot; J., Joubert; G., Juhasz; H., Jullian; H., Kafe; P., Kelly; J., Kidney; K., Killian; H., Kinch; D. L., Kirsten; U., Kleinecke Pohl; K., Korlipara; L. P., Krige; A., Kroker; A. F., Kuipers; M., Labrecque; P., Larivee; C., Laskowitz; C., Le Merre; F., Lemoigne; A., Ludwig Sengpiel; M., Luengo; R., Luton; W., Macnee; S. M., Ali; F., Maltais; A., Mansur; D., Marciniuk; A., Marin; P., Martin; J. B., Martinot; F., Mazza; M. C., Bride; B., Mcdonald; C., Mckinnon; A., Mclvor; D., Mcnally; P. M., Mengeot; J., Messner; G., Moder; P., Mooney; A. M., Moretti; D., Muller; C., Murio; S., Nardini; A., Nel; Ochoa, ; D. E., Saracho Jo; P., Paggiaro; B., Paradis; J., Patrick; R., Peche; C., Pellicer; T., Perez; E., Perez; L. A., De Llano; G., Philteos; W. R., Pieters; B., Pigearias; W., Pohl; R., Popovic; M., Prins; H., Querfurt; K., Rajkay; G., Ras; J., Road; J., Roig; A. C., Roldaan; M., Rolke; D., Rozen; F., Sanchez Toril; N., Savani; L., Savary; M., Schiavina; H., Schiesbühl; A. J., Schreurs; W., Schröder Babo; W., Schurmann; V., Seiz; C., Sevette; R., Sharma; C., Shum; H. E., Damsté; A., Smithers; J. J., Soler; H., Steffen; U., Steinhauser; M., Sweilem; G., Tellier; B., Terol; Terzano, Claudio; M., Timar; G., Toma; P. T., Monserrat; H. A., Trauth; E., Valyon; Brande Van, Den; J. A., Van Noord; J. V., Vaquer; H. V., Hernandez Hector; G., Vereecken; C., Verkindre; M., Vigh; J. J., Viljoen; W., Vincken; I., Vinkler; S., Visser; L., Volgmann; W., Vorderstrasse; R., Voves; F., Vrancken; H. H., Weber; P. L., Wielders; P., Willoughby; J., Wurtz; W., Yang; M., Zabaleta; W., Zachgo; A., Zanini; M., Zeiner; M., Zeiner; H., Michael; J., Grillenberger; G., Holub; R., Popovic; J., Wurtz; G., Duschek; W., Janistyn; C., Hutter; H., Schiesbühl; J., Messner; W., Pohl; M., Sweilem; R., Voves; W., Holler; G., Moder; W., Vincken; M., Decramer; J. B., Martinot; L., Croonenborghs; D., Rozen; G., Vereecken; W., Denier; A., Flemale; F., Vrancken; A., Delobbe; Frognier, ; R., Peche; Brande Van, Den; A., Delobbe; P. M., Mengeot; F., Maltais; J., Bourbeau; A., Mclvor; P., Larivee; B., Craig; J., Road; P. A., Houle; W., Yang; K. R., Chapman; M., Gagnon; R., Luton; P., Hernandez; L., Homik; D., Marciniuk; S., Henein; V., Hoffstein; K., Killian; B., Paradis; J., Carter; M., Labrecque; P., Willoughby; R., Abdulla; G., Philteos; V., Chan; A., Dhar; G., Tellier; P., Hyvernat; T., Perez; H., Kafe; J., Dupouy; P., Coulet; B., Pigearias; H., Jullian; L., Fouquert; G. R., Boyer; L., Bernabeu; C., Verkindre; A., Bettendorf; J. Y., Jasnot; Aguilaniu, ; L., Savary; F., Bonnaud; F., Lemoigne; C., Sevette; P., Greillier; D., Muller; B., Terol; C., Le Merre; M., Hoefer; H. A., Trauth; H., Querfurt; L., Volgmann; U., Steinhauser; T., Ginko; K. H., Franz; A., Kroker; W., Schröder Babo; U., Gehling; P., Martin; A., Ludwig Sengpiel; T., Dapper; W., Zachgo; U., Kleinecke Pohl; M., Rolke; L., Blecher; H., Steffen; H., Grygier; H. H., Weber; W., Vorderstrasse; W., Schurmann; C., Laskowitz; V., Seiz; B., Gross; B. B., Von Der Heydt; E., Valyon; M., Czompó; G., Juhasz; Z., Gyori; M., Timar; I., Albert; K., Rajkay; E., Bauchnect; I., Vinkler; B., Balint; M., Vigh; S., Amaducci; G. W., Canonica; G., Di Maria; A., Zanini; P., Paggiaro; M., Schiavina; R. W., Dal Negro; F., Mazza; G., Toma; C., Bucca; C., Terzano; G., Garelli; A. M., Moretti; S., Nardini; L., Fabbri; M. P., Barbaro; G. W., Canonica; E., Clini; P. L., Wielders; A. F., Kuipers; C. S., De Graaff; D., Cheung; H. E., Damsté; W. R., Pieters; A. J., Schreurs; J. A., Van Noord; D. R., De Munck; T. A., Bantje; A. C., Roldaan; E. M., Irusen; G., Ras; M., Prins; E., Bateman; J., Joubert; I., Abdullah; S., Visser; A. H., Bruning; J. J., Viljoen; L. P., Krige; A., Nel; D. L., Kirsten; J. L., Izquierdo; Mdel M., Garcia; C., Shum; E., Chiner; J. L., Heredia; M., Zabaleta; M., Luengo; D. E., Saracho Jo; P. T., Monserrat; J. V., Vaquer; A., Marin; J., Angrill; C., Brotons; A., Altés; E., Perez; F., Sanchez Toril; Pde L., Ramos; H. V., Hernandez Hector; C., Almonacid; J., Belda; J. M., Antonana; R., Blanquer; J. J., Soler; F., Barbe; C., Murio; L., De Teresa; C., Esteban; J. V., Greses; C., Pellicer; J., Echave; L. A., De Llano; J., Roig; A., Chopra; N., Savani; B., Glekin; A., Jackson; M., Blagden; R., Sharma; G., Chapman; D., Mcnally; J., Patrick; M. C., Bride; G. E., Burns; J., Kidney; P., Kelly; W., Macnee; H., Kinch; S. M., Ali; M., Adler; M., Blagden; P., Mooney; Caldwell, ; I. S., Farmer; A., Graham; K., Holgate; P., Fletcher; K., Korlipara; B., Mcdonald; C., Mckinnon; A., Smithers; A., Mansur; T., Gooding; Harper, Ochoa; Foden,. - In: THE LANCET. - ISSN 0140-6736. - 374:9691(2009), pp. 695-703. [10.1016/s0140-6736(09)61252-6]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/107933
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 146
  • Scopus 545
  • ???jsp.display-item.citation.isi??? 434
social impact